Medical World News® Inside the Practice: CancerNetwork® With Anthony W. Tolcher, MD, and Alexander I. Spira, MD, PhD, on Expand Access to Phase 1 Cancer Trials

For the latest installment of the Inside the Practice Segment of the Medical World News® broadcast, CancerNetwork® spoke with Anthony W. Tolcher, MD, co-founder of NEXT Oncology and a mMedical oOncologist at Texas Oncology, as well as Alexander I. Spira, MD, PhD, Medical Oncologist and dDirector of Virginia Cancer Specialists Research Institute and the Phase I Trial Program, to discuss their new …

What Did We Learn From IMpower010 in Resectable NSCLC

What the New KRAS Inhibitor Means for Lung Cancer

Last month, the FDA granted accelerated approval of sotorasib (Lumakras) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), following the results of the phase II CodeBreaK 100 trial, data from which were presented during the recent virtual American Society of Clinical Oncology annual meeting. In this second of four exclusive episodes, MedPage Today brought together three leaders in the field —  moderator Vinay Prasad, MD, …

What Did We Learn From IMpower010 in Resectable NSCLC

Genomic Test in Lung Cancer: Waiting Is the Hardest Part

— Our expert roundtable discusses how they the treat NSCLC patients who are waiting on NGS results Next-generation sequencing (NGS) is recommended by the National Comprehensive Cancer Network (NCCN) for all patients with non-small cell lung cancer (NSCLC). Several studies at the recent American Society of Clinical Oncology virtual annual meeting explored the application of biomarker testing in the U.S., as well …

What Did We Learn From IMpower010 in Resectable NSCLC

What Did We Learn From IMpower010 in Resectable NSCLC

At the recent virtual American Society of Clinical Oncology annual meeting, results of the phase III IMpower010 trial demonstrated that adjuvant atezolizumab (Tecentriq) for patients with stage IB to IIIA non-small cell lung cancer (NSCLC) improved disease-free survival in patients with high PD-L1 expression. In this first of four exclusive episodes, MedPage Today brought together three leaders in the field —  moderator Vinay Prasad, MD, of the University …

YourSA Best Oncologist: NEXT Oncology

Dr. Anthony Tolcher’s dedication to medical advancements and innovative approaches at NEXT Oncology has earned the practice Best Oncologist in San Antonio in the 2021 Readers’ Choice Awards. NEXT Oncology has made strides in patient care, especially over the past year. As a Phase 1 research center, patient safety is critical. Patients on clinical trials are faced with even greater …

SITC Conference 2019

Novel Drug Active in Anti-PD-1/L1 Resistant Tumors

NATIONAL HARBOR, Md. — A novel immunomodulatory therapy demonstrated antitumor activity across a broad range of heavily pretreated, immunotherapy-resistant tumors, including objective responses in advanced non-small cell lung cancer (NSCLC), a preliminary study showed. Treatment with the Siglec-15-targeted monoclonal antibody NC318 led to disease control (response and stable disease) in one-third of the 49 patients on study. The activity included …

Christus campus new HQ home for expanding cancer research group

Next Oncology, launched a year ago in San Antonio, is moving its headquarters to the Christus Santa Rosa Hospital-Medical Center campus as the phase I cancer research organization advances plans for expansion in the U.S. and abroad. Next Oncology has signed an 11-year lease for nearly 20,000 square feet at Christus’ Medical Center Tower I. It was initially operating in …

Lack of Clinical Trial Participants Slowing Cancer Drug Development

Lack of Clinical Trial Participants Slowing Cancer Drug Development

Hundreds of cancer drugs are in the pipeline with the potential to save millions of lives, and make even more inroads into this dreaded disease. But may of the tests are stalled, due to a lack of people willing to participate in the clinical trials which are required before a cancer drug can win approval, News Radio 1200 WOAI reports. …

Should We Stop Referring to 'Cancer Survivors?'

Should We Stop Referring to ‘Cancer Survivors?

A study by Texas A&M University suggests that we no longer use the phrase ‘cancer survivor’ to refer to former cancer patients, and prominent San Antonio oncologist Dr. Anthony Tolcher agrees, News Radio 1200 WOAI reports. “Many people, it seems, don’t particularly like that term,” said Dr. Tolcher, who is the Director of Clinical Research at Next Oncology and Texas …

FDA calls new melanoma treatment a breakthrough

July is UV Awareness Month, making it a good time to remind you that one in five Americans will develop skin cancer at some point in their lives. Local doctors are now revealing the research they participated in that found a breakthrough treatment for melanoma. Read more on News 4 San Antonio